Looking to publish in European Heart Journal - Cardiovascular Pharmacotherapy? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowEuropean Heart Journal – Cardiovascular Pharmacotherapy is an ESC Publications journal focused on cardiovascular medicine and pharmacology. It became fully Open Access from January 2025, with all accepted submissions from 3 September 2024 publishing under an Open Access license. The journal reports a 2024 Impact Factor of 6.1 and a 2024 CiteScore of 11.2.
Looking to publish in European Heart Journal - Cardiovascular Pharmacotherapy? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
European Heart Journal - Cardiovascular Pharmacotherapy accepts the following article types. Click on an article type to view submission instructions.
Original Articles
Reviews
Correspondence
Letters
Rapid Communications
Recent Publications
Bleeding risk assessment in patients with new-onset atrial fibrillation after CABG
Anders Jeppsson, Mary Rezk, Florian E M Herrmann
The Anticoagulation Dilemma in Postoperative Atrial Fibrillation after Cardiac Surgery
Hanne Berg Ravn, Milan Milojevic
Bleeding Risk Assessment in CABG-Related Postoperative Atrial Fibrillation: Clinical Interpretation and Future Directions
Xubo Zhao, Lingfan Sun
A bleeding score identifies who bleeds, not who benefits: anticoagulation decisions in postoperative atrial fibrillation after coronary surgery
Xiang Zhou, Hongyan Liu, Zhengdong Hua
Statin adherence among patients with hypertension in Swedish primary health care: a QregPV cohort study using explainable machine learning
Johan Sandslätt, Kristina Bengtsson Boström, Maria Åberg, Johan-Emil Bager, Koen Simons, Georgios Mourtzinis, Per Hjerpe, Tobias Andersson
Frequently asked questions
How long does it take to publish?
First decision within an average of 9 days. Accepted manuscripts are aimed to be published on Advance Access within 2 days of receipt at OUP if the licence to publish is signed promptly. Proof corrections must be returned within 3 days.
Reformat to European Heart Journal - Cardiovascular Pharmacotherapy using Livewrite PremiumIs a cover letter required?
A cover letter is used in specific situations. Authors should indicate in the cover letter if an Editor or Associate Editor from the journal is a co-author or contributor, and AI use should be disclosed in a cover letter at submission.
Reformat to European Heart Journal - Cardiovascular Pharmacotherapy using Livewrite PremiumWhat are the publication costs?
An Article Processing Charge may be payable. The journal has no submission fees. Eligible ESC members receive a 20% APC discount, and partial or full APC waivers may be available for corresponding authors in eligible LMIC countries.
Reformat to European Heart Journal - Cardiovascular Pharmacotherapy using Livewrite Premium